



| | |
|---|--|
| CONTRACTING PARTY/ PARTIE CONTRACTANTE | |
| RESPONSIBLE FOR HS MATTERS IN YOUR ADMINISTRATION/ RESPONSABLE DU SH DANS VOTRE ADMINISTRATION | |
| ADDRESS/ ADRESSE | |
| DATE AND SIGN/ DATE ET SIGNATURE | |

**HS (2017 EDITION) CLASSIFICATION OF INN PRODUCTS (INN LIST 119)
SH (2017 EDITION) CLASSEMENT DES PRODUITS DCI (LISTE DE DCI 119)**

| INN/ DCI* | HS (2017) Classification proposed by the Secretariat/ Classement dans le SH (2017) proposé par le Secrétariat | Classification and Comments by Administrations / Classement et observations des administrations |
|--|--|--|
| abelacimab / abélacimab | 3002.13 Immunological product/ Produit immunologique | |
| abivertinib / abivertinib | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| adriforant / adriforant | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| alteminostat / altéminostat | 2933.59 Piperazine ring/ Cycle pipérazine | |
| amelparib / amelparib | 2934.99 N,O-ring/ N,O-cycle | |
| amlivirsén / amlivirsén | 2934.99 Nucleic acid/ Acide nucléique | |
| amprelosetine / ampréloxétine | 2933.39 Pyridine ring/ Cycle pyridine | |
| asalhydromorphone / asalhydromorphone | 2939.19 Opioid analgesic / Analgésique opioïde | |
| aticaprant / | 2933.99 | |

| | | |
|--|---|--|
| aticaprant | N-ring/ N-cycle | |
| avasopasem manganese / avasopasem manganèse | 2933.39 Pyridine ring/ Cycle pyridine | |
| avoplace / avoplace | 3002.90 Cell therapy/ Thérapie cellulaire | |
| azelaprag / azélaprag | 2935.90 Sulphonamide/ Sulfonamide | |
| bamadutide / bamadutide | 2934.99 Nucleic acid/ Acide nucléique | |
| bempegaldesleukin / bempégaldesleukine | 3002.13 Immunological product/ Produit immunologique | |
| bevifimod / bévifimod | 3002.13 Immunological product/ Produit immunologique | |
| bintrafusp alfa / bintrafusp alfa | 3002.13 Immunological product/ Produit immunologique | |
| birtamimab / birtamimab | 3002.13 Immunological product/ Produit immunologique | |
| brilaroxazine / brilaroxazine | 2934.99 N,O-ring/ N,O-cycle | |
| budigalimab / budigalimab | 3002.13 Immunological product/ Produit immunologique | |
| camsirubicin / camsirubicine | 2932.99 O-ring/ O-cycle | |
| cemiplimab / cémiplimab | 3002.13 Immunological product/ Produit immunologique | |
| cenupatide / cénupatide | 2925.29 Imine/ Imine | |
| ceralasertib / céralasertib | 2934.99 N,O-ring/ N,O-cycle | |
| cimlanod / cimlanod | 2935.90 Sulphonamide/ Sulfonamide | |
| cintirorgon / cintirorgon | 2935.90 Sulphonamide/ Sulfonamide | |
| coblopasvir / coblopasvir | 2934.99 N,O-ring/ N,O-cycle | |
| cotadutide / cotadutide | 2934.99 Nucleic acid/ Acide nucléique | |
| crovalimab / crovalimab | 3002.13 Immunological product/ Produit immunologique | |

| | | |
|--|---|--|
| danicopan / danicopan | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| dersimelagon / dersimélagon | 2933.39 Pyridine ring/ Cycle pyridine | |
| dilanubicel / dilanubicel | 3002.90 Cell therapy/ Thérapie cellulaire | |
| dilpacimab / dilpacimab | 3002.13 Immunological product/ Produit immunologique | |
| dostarlimab / dostarlimab | 3002.13 Immunological product/ Produit immunologique | |
| durlobactam / durlobactam | 2933.99 N-ring/ N-cycle | |
| eftozanermin alfa / eftozanermine alfa | 3002.13 Immunological product/ Produit immunologique | |
| eladocagene exuparvovec / éladocagène exuparvovec | 3002.90 Virus/ Virus | |
| elopultide / élopultide | 2934.99 Nucleic acid/ Acide nucléique | |
| eluforsen / éluforsen | 2934.99 Nucleic acid/ Acide nucléique | |
| encequidar / encéquidar | 2934.99 N,O-ring/ N,O-cycle | |
| ensifentrine / ensifentrine | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| exicorilant / exicorilant | 2935.90 Sulphonamide/ Sulfonamide | |
| fosgemcitabine palabenamide / fosgemcitabine palabénamide | 2934.99 N,O-ring/ N,O-cycle | |
| fosifloxuridine nafalbenamide / fosifloxuridine nafalbénamide | 2934.99 N,O-ring/ N,O-cycle | |
| foslinanib / foslinanib | 2933.99 N-ring/ N-cycle | |

| | | |
|--|---|--|
| fosmanogepix / fosmanogépix | 2934.99 N,O-ring/ N,O-cycle | |
| frovocimab / frovocimab | 3002.13 Immunological product/ Produit immunologique | |
| futibatinib / futibatinib | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| galicafator / galicafator | 2932.99 O-ring/ O-cycle | |
| gancotamab / gancotamab | 3002.13 Immunological product/ Produit immunologique | |
| golexanolone / golexanolone | 2937.29 Hormone derivative/ Dérivé de l'hormone | |
| gosuranemab / gosuranémab | 3002.13 Immunological product/ Produit immunologique | |
| hydromethylthionine / hydrométhylthionine | 2934.99 N,S-ring/ N,S-cycle | |
| iadademstat / iadademstat | 2921.59 Aromatic polyamine/ Polyamine aromatique | |
| idecabtagene vicleucel / idécabtagène vicleucel | 3002.90 Cell therapy/ Thérapie cellulaire | |
| ilginatinib / ilginatinib | 2933.39 Pyridine ring/ Cycle pyridine | |
| iodine (¹³¹I) apamistamab / iode (¹³¹I) apamistamab | 2844.40 Radioactive compound/ Composé radioactif | |
| lenzumestrocel / lenzumestrocel | 3002.90 Cell therapy/ Thérapie cellulaire | |
| leriglitazone / lériglitazone | 2934.10 thiazole-ring/ thiazole-cycle | |
| linrodostat / linrodostat | 2933.49 Quinoline ring/ Cycle quinoléine | |
| lisocabtagene maraleucel / lisocabtagène maraleucel | 3002.90 Cell therapy/ Thérapie cellulaire | |
| marstacimab / marstacimab | 3002.13 Immunological product/ Produit immunologique | |
| masupirdine / | 2935.90 Sulphonamide/ Sulfonamide | |

| | | |
|--|--|--|
| masupirdine | | |
| miricorilant / miricorilant | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| mivavotinib / mivavotinib | 2933.79 Lactam/ Lactame | |
| murlentamab / murlentamab | 3002.13 Immunological product/ Produit immunologique | |
| neluxicapone / néluxicapone | 2926.90 Nitrile function compound/ Composé à fonction nitrile | |
| nerinetide / nérinétide | 2934.99 Nucleic acid/ Acide nucléique | |
| nevanimibe / névanimibe | 2924.29 Cyclic amide/ Amide cyclique | |
| nirsevimab / nirsévimab | 3002.13 Immunological product/ Produit immunologique | |
| nomacopan / nomacopan | 2934.99 Nucleic acid/ Acide nucléique | |
| obexelimab / obéxélimab | 3002.13 Immunological product/ Produit immunologique | |
| odevixibat / odévixibat | 2935.90 Sulphonamide/ Sulfonamide | |
| olacافتor / olacافتor | 2935.90 Sulphonamide/ Sulfonamide | |
| olenasufigene relduparvovec / olénasufigène relduparvovec | 3002.90 Virus/ Virus | |
| olinvacimab / olinvacimab | 3002.13 Immunological product/ Produit immunologique | |
| olorinab / olorinab | 2933.99 N-ring/ N-cycle | |
| omburtamab / omburtamab | 3002.13 Immunological product/ Produit immunologique | |
| ontamalimab / ontamalimab | 3002.13 Immunological product/ Produit immunologique | |
| orilanolimab / | 3002.13 | |

| | | |
|--|---|--|
| orilanolimab | Immunological product/ Produit immunologique | |
| osocimab / osocimab | 3002.13 Immunological product/ Produit immunologique | |
| otilimab / otilimab | 3002.13 Immunological product/ Produit immunologique | |
| prademagene zamikeracel / pradémagène zamikéracel | 3002.90 Cell therapy/ Thérapie cellulaire | |
| prolgolimab / prolgolimab | 3002.13 Immunological product/ Produit immunologique | |
| redipultide / rédiptulide | 2934.99 Nucleic acid/ Acide nucléique | |
| relatlimab / rélatlimab | 3002.13 Immunological product/ Produit immunologique | |
| reldesemtiv / reldésemtiv | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| reproxalap / réproxalap | 2933.49 Quinoline ring/ Cycle quinoléine | |
| resmetirom / resmétirom | 2933.69 Triazine-ring/ Cycle triazine | |
| ripretinib / ripréтинib | 2933.79 Lactam/ Lactame | |
| rocacetrapiб / rocacétrapiб | 2934.99 N,O-ring/ N,O-cycle | |
| rodatristat / rodatristat | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| rolinsatamab / rolinsatamab | 3002.13 Immunological product/ Produit immunologique | |
| rolinsatamab talirine / rolinsatamab talirine | 3002.13 Immunological product/ Produit immunologique | |
| roluperidone / rolupéridone | 2933.79 Lactam/ Lactame | |
| rovafovir etalafenamide / rovafovir étalafénamide | 2934.99 N,O-ring/ N,O-cycle | |
| ruxotemitide / ruxotémítide | 2933.99 N-ring/ N-cycle | |

| | | |
|--|---|--|
| selatogrel / sélatogrel | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| setogepram / séto gépram | 2916.39 Aromatic monocarboxylic acid/ Acide monocarboxylique aromatique | |
| sintilimab / sintilimab | 3002.13 Immunological product/ Produit immunologique | |
| siremadlin / sirémadline | 2933.79 Lactam/ Lactame | |
| soticlestat / soticlestat | 2933.39 Pyridine ring/ Cycle pyridine | |
| spesolimab / spésolimab | 3002.13 Immunological product/ Produit immunologique | |
| tabituximab / tabituximab | 3002.13 Immunological product/ Produit immunologique | |
| tabituximab barzuxetan / tabituximab barzuxétan | 3002.13 Immunological product/ Produit immunologique | |
| tafasitamab / tafasitamab | 3002.13 Immunological product/ Produit immunologique | |
| talditercept alfa / talditercept alfa | 3002.13 Immunological product/ Produit immunologique | |
| taniborbactam / taniborbactam | 2934.99 B,O-ring/ B,O-cycle | |
| tavapadon / tavapadon | 2933.59 Pyrimidine ring/ Pyrimidine cycle | |
| telaglenastat / télaglénastat | 2934.99 N,S-ring/ N,S-cycle | |
| temelimab / témélimab | 3002.13 Immunological product/ Produit immunologique | |
| teserpaturev / téserpaturev | 3002.90 Virus/ Virus | |
| tildacerfont / tildacerfont | 2934.10 Thiazole-ring/ Cycle thiazole | |
| tirbanibulin / tirbanibuline | 2934.99 N,O-ring/ N,O-cycle | |
| tirzepatide / | 2934.99 | |

| | | |
|---------------------------------------|---|--|
| tirzépatide | Nucleic acid/ Acide nucléique | |
| tofersen / tofersen | 2934.99 Nucleic acid/ Acide nucléique | |
| toripalimab / toripalimab | 3002.13 Immunological product/ Produit immunologique | |
| umibecestat / umibécestat | 2934.99 N,O-ring/ N,O-cycle | |
| vafidemstat / vafidemstat | 2934.99 N,O-ring/ N,O-cycle | |
| valecobulin / valécobuline | 2934.10 Thiazole-ring/ Cycle thiazole | |
| zampilimab / zampilimab | 3002.13 Immunological product/ Produit immunologique | |

* "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2013" published by the WHO (Stem Book 2013). http://www.who.int/medicines/services/inn/StemBook_2013_Final.pdf?ua=1